Innovation is central to Uniphar’s approach to the progression and development of new drug therapies, providing the link between brand strategy and commercial launch. We apply clinical and commercial expertise to help design and manage new product access schemes. We achieve effective results, with clear patient, customer and brand benefits.
Our teams provide:
The result provides our customers with a collaborative partner that shares their ambitions for success.
Uniphar has developed sustainable and effective models that help manage complex relationships with all project stakeholders.
Collaboration is an essential ingredient of all of our access programs. This includes upstream activity with our manufacturing clients and regulators and all downstream activity with healthcare professionals and patients… whether they are individuals or part of a patient group that we have helped to formulate and design the new care regime. This level of immediacy ensures that our performance can be measured on a constant and consistent basis throughout the lifecycle of each ACCESS project.
Achieving measurable and positive results is central to all of Uniphar’s activities in the rapidly changing environment that drives access to new drug treatments and devices.
Real world evidence that utilises an effective data collection and management platform ensures that data remains central to our reporting solutions and has a minimal burden on participating HCPs. Equally, it enhances the patient experience and influences positive outcomes.
Our flexible approach to patient access needs, across all stages of the product cycle, whatever the disease or therapeutic area, ensures that we are able to support all appropriate care locations.
Manufacturers, health providers and patients require earlier access to innovative therapies. Simultaneously, it’s important that treatment costs are minimised.
Uniphar’s ACCESS programs provide the clinical, commercial and regulatory wrapper that ensures market entry is achieved quickly and efficiently. Partnership and collaboration with care providers, ensures that long-term sustainable commercial models are fully evaluated and the most efficient model established.
Reducing time to market is central to Uniphar’s ACCESS programs. Agile program management ensures that we minimise project timelines and maximise patient access to new treatments and therapies.